<p>Zimmer Biomet（纽约证券交易所代码：ZBH - 获取免费报告）在周五发布的报告中，分析师 Stifel Nicolaus 将其目标价格从 115.00 美元上调至 118.00 美元，Benzinga 报道。该公司目前对这家医疗设备提供商的股票给予 “买入” 评级。Stifel Nicolaus 的目标价格意味着该公司股价有 17.47% 的潜在上涨空间。</p>
<ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
<p>其他一些研究分析师最近也对该公司发布了报告。Raymond James Financial 将 Zimmer Biomet 的目标价格从 104.00 美元上调至 113.00 美元，并在 8 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。加拿大皇家银行将 Zimmer Biomet 的目标价格从 112.00 美元上调至 115.00 美元，并在 8 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。Redburn Partners 在周四设定了 Zimmer Biomet 的目标价格为 130.00 美元。Rothschild Redb 在周四的研究报告中将 Zimmer Biomet 的评级提升至 “强力买入”。最后，Rothschild &amp; Co Redburn 在周四的研究报告中开始覆盖 Zimmer Biomet，给予 “买入” 评级和 130.00 美元的目标价格。一位投资分析师对该股票给予 “强力买入” 评级，十位分析师给予 “买入” 评级，七位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 113.16 美元。</p>
<p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
<p><strong>阅读我们关于 Zimmer Biomet 的最新研究报告</strong></p>
<h2>Zimmer Biomet 股价上涨 0.2%</h2>
<ul>
<li>2 家机器人手术公司挑战 Intuitive Surgical 的领先地位</li>
</ul>
<p>周五午盘交易中，ZBH 股价上涨 0.24 美元，达到 100.45 美元。该公司交易了 288,498 股，较其平均交易量 1,964,456 股有所减少。该公司的市值为 199 亿美元，市盈率为 24.44，市盈率/增长比率为 2.30，贝塔值为 0.68。Zimmer Biomet 的 1 年最低价为 89.22 美元，1 年最高价为 114.72 美元。该公司的 50 日移动平均价格为 99.93 美元，200 日移动平均价格为 99.46 美元。该公司的速动比率为 0.96，流动比率为 1.87，债务与股本比率为 0.54。</p>
<p>Zimmer Biomet（纽约证券交易所代码：ZBH - 获取免费报告）最后一次公布财报是在 8 月 7 日，医疗设备提供商报告该季度每股收益为 2.07 美元，超出市场共识预期的 1.98 美元，超出 0.09 美元。该公司该季度的收入为 20.8 亿美元，而市场共识预期为 20.6 亿美元。Zimmer Biomet 的股本回报率为 12.76%，净利润率为 10.51%。该公司的季度收入较去年同期增长了 7.0%。在去年同期，该公司每股收益为 2.01 美元。Zimmer Biomet 已将其 2025 财年的指导目标设定为每股收益 8.100-8.300 美元。整体来看，股票分析师预测 Zimmer Biomet 在当前财年将发布每股收益 8.22 美元。</p>
<h2>内部活动</h2>
<ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
<p>在其他新闻中，SVP Lori Winkler 在 9 月 8 日的交易中出售了 1,500 股该公司的股票。股票以 104.15 美元的平均价格出售，总价值为 156,225.00 美元。交易完成后，这位高级副总裁直接持有该公司 6,833 股股票，价值 711,656.95 美元。这代表其持股比例减少了 18.00%。该交易已在与 SEC 的法律文件中披露，文件可通过此链接获取。当前 1.39% 的股票由公司内部人士持有。</p>
<h2>对 Zimmer Biomet 的对冲基金看法</h2>
<p>几家机构投资者最近修改了对 ZBH 的持股。Garde Capital Inc.在第一季度购买了价值约 29,000 美元的 Zimmer Biomet 新股份。Menard Financial Group LLC 在第四季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。Washington Trust Advisors Inc.在第一季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。Columbia River Financial Group LLC 在第一季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。最后，Cary Street Partners Investment Advisory LLC 在第二季度将其在 Zimmer Biomet 的股份提高了 83.7%。Cary Street Partners Investment Advisory LLC 现在拥有 327 股该医疗设备提供商的股票，价值 30,000 美元，此前在上个季度又购买了 149 股。88.89% 的股票由机构投资者持有。</p>
<h2>关于 Zimmer Biomet</h2>
<p>（获取免费报告）</p>
<p>Zimmer Biomet Holdings, Inc 及其子公司在全球范围内运营，作为一家医疗技术公司。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T.产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及固定和稳定胸部骨骼的产品，以促进心脏手术、创伤或胸部畸形后的愈合或重建。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Zimmer Biomet</li>
<li>异常交易量的股票：如何实时找到异常交易量股票</li>
<li>亚马逊可能在十月达到历史新高的三个原因</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>Workday 上涨……达到新的历史高股价</li>
<li>卖空 - 利弊分析</li>
<li>麦当劳：新的历史高点是不可避免的</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
<p>在考虑 Zimmer Biomet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Zimmer Biomet 并不在名单上。</p>
<p>虽然 Zimmer Biomet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Stifel Nicolaus 将 Zimmer Biomet (NYSE:ZBH) 的目标价从 115.00 美元上调至 118.00 美元，维持 “买入” 评级。这个新目标暗示相较于前一交易日收盘价有 17.47% 的潜在上涨空间。其他分析师也提高了他们的目标价，平均目标为 113.16 美元。Zimmer Biomet 的股票目前交易价格为 100.45 美元，市值为 199 亿美元。该公司报告的季度每股收益为 2.07 美元，超出预期，并已将 2025 财年的指引设定为每股收益 8.100-8.300</p>

<p>Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective boosted by analysts at Stifel Nicolaus from $115.00 to $118.00 in a report issued on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the medical equipment provider's stock. Stifel Nicolaus' price objective points to a potential upside of 17.47% from the company's previous close.</p>
<div class="lb-trans"><p>Zimmer Biomet（纽约证券交易所代码：ZBH - 获取免费报告）在周五发布的报告中，分析师 Stifel Nicolaus 将其目标价格从 115.00 美元上调至 118.00 美元，Benzinga 报道。该公司目前对这家医疗设备提供商的股票给予 “买入” 评级。Stifel Nicolaus 的目标价格意味着该公司股价有 17.47% 的潜在上涨空间。</p>
</div><ul>
<li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on the company. Raymond James Financial boosted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, August 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday. Rothschild Redb raised Zimmer Biomet to a &#34;strong-buy&#34; rating in a research report on Thursday. Finally, Rothschild &amp; Co Redburn initiated coverage on Zimmer Biomet in a research report on Thursday. They issued a &#34;buy&#34; rating and a $130.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $113.16.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对该公司发布了报告。Raymond James Financial 将 Zimmer Biomet 的目标价格从 104.00 美元上调至 113.00 美元，并在 8 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。加拿大皇家银行将 Zimmer Biomet 的目标价格从 112.00 美元上调至 115.00 美元，并在 8 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。Redburn Partners 在周四设定了 Zimmer Biomet 的目标价格为 130.00 美元。Rothschild Redb 在周四的研究报告中将 Zimmer Biomet 的评级提升至 “强力买入”。最后，Rothschild &amp; Co Redburn 在周四的研究报告中开始覆盖 Zimmer Biomet，给予 “买入” 评级和 130.00 美元的目标价格。一位投资分析师对该股票给予 “强力买入” 评级，十位分析师给予 “买入” 评级，七位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 113.16 美元。</p>
</div><p>Get <strong>Zimmer Biomet</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
</div><p><strong>Read Our Latest Research Report on Zimmer Biomet</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Zimmer Biomet 的最新研究报告</strong></p>
</div><h2>Zimmer Biomet Trading Up 0.2%</h2>
<div class="lb-trans"><h2>Zimmer Biomet 股价上涨 0.2%</h2>
</div><ul>
<li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家机器人手术公司挑战 Intuitive Surgical 的领先地位</li>
</ul>
</div><p>ZBH traded up $0.24 during midday trading on Friday, hitting $100.45. 288,498 shares of the company were exchanged, compared to its average volume of 1,964,456. The firm has a market capitalization of $19.90 billion, a P/E ratio of 24.44, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $114.72. The firm's 50 day moving average price is $99.93 and its 200-day moving average price is $99.46. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.</p>
<div class="lb-trans"><p>周五午盘交易中，ZBH 股价上涨 0.24 美元，达到 100.45 美元。该公司交易了 288,498 股，较其平均交易量 1,964,456 股有所减少。该公司的市值为 199 亿美元，市盈率为 24.44，市盈率/增长比率为 2.30，贝塔值为 0.68。Zimmer Biomet 的 1 年最低价为 89.22 美元，1 年最高价为 114.72 美元。该公司的 50 日移动平均价格为 99.93 美元，200 日移动平均价格为 99.46 美元。该公司的速动比率为 0.96，流动比率为 1.87，债务与股本比率为 0.54。</p>
</div><p>Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Zimmer Biomet（纽约证券交易所代码：ZBH - 获取免费报告）最后一次公布财报是在 8 月 7 日，医疗设备提供商报告该季度每股收益为 2.07 美元，超出市场共识预期的 1.98 美元，超出 0.09 美元。该公司该季度的收入为 20.8 亿美元，而市场共识预期为 20.6 亿美元。Zimmer Biomet 的股本回报率为 12.76%，净利润率为 10.51%。该公司的季度收入较去年同期增长了 7.0%。在去年同期，该公司每股收益为 2.01 美元。Zimmer Biomet 已将其 2025 财年的指导目标设定为每股收益 8.100-8.300 美元。整体来看，股票分析师预测 Zimmer Biomet 在当前财年将发布每股收益 8.22 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
</div><p>In other news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，SVP Lori Winkler 在 9 月 8 日的交易中出售了 1,500 股该公司的股票。股票以 104.15 美元的平均价格出售，总价值为 156,225.00 美元。交易完成后，这位高级副总裁直接持有该公司 6,833 股股票，价值 711,656.95 美元。这代表其持股比例减少了 18.00%。该交易已在与 SEC 的法律文件中披露，文件可通过此链接获取。当前 1.39% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Zimmer Biomet</h2>
<div class="lb-trans"><h2>对 Zimmer Biomet 的对冲基金看法</h2>
</div><p>Several institutional investors have recently modified their holdings of ZBH. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Menard Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $30,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. 88.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近修改了对 ZBH 的持股。Garde Capital Inc.在第一季度购买了价值约 29,000 美元的 Zimmer Biomet 新股份。Menard Financial Group LLC 在第四季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。Washington Trust Advisors Inc.在第一季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。Columbia River Financial Group LLC 在第一季度购买了价值约 30,000 美元的 Zimmer Biomet 新股份。最后，Cary Street Partners Investment Advisory LLC 在第二季度将其在 Zimmer Biomet 的股份提高了 83.7%。Cary Street Partners Investment Advisory LLC 现在拥有 327 股该医疗设备提供商的股票，价值 30,000 美元，此前在上个季度又购买了 149 股。88.89% 的股票由机构投资者持有。</p>
</div><h2>About Zimmer Biomet</h2>
<div class="lb-trans"><h2>关于 Zimmer Biomet</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.</p>
<div class="lb-trans"><p>Zimmer Biomet Holdings, Inc 及其子公司在全球范围内运营，作为一家医疗技术公司。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T.产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及固定和稳定胸部骨骼的产品，以促进心脏手术、创伤或胸部畸形后的愈合或重建。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Zimmer Biomet</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>3 Reasons Amazon Could Be at an All-Time High by October</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Workday Rising… To Fresh Record High Stock Prices</li>
<li>Short Selling - The Pros and Cons</li>
<li>McDonald’s: New All-Time Highs Are Inevitable</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Zimmer Biomet</li>
<li>异常交易量的股票：如何实时找到异常交易量股票</li>
<li>亚马逊可能在十月达到历史新高的三个原因</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>Workday 上涨……达到新的历史高股价</li>
<li>卖空 - 利弊分析</li>
<li>麦当劳：新的历史高点是不可避免的</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ZBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
</div><p>Before you consider Zimmer Biomet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Zimmer Biomet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Zimmer Biomet 并不在名单上。</p>
</div><p>While Zimmer Biomet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zimmer Biomet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zimmer Biomet（纽约证券交易所代码：ZBH）被 Stifel Nicolaus 设定了新的目标价为 118.00 美元